Does Rallies show 13F holders for URGN?

Yes. Rallies tracks hedge fund and 13F ownership data for URGN, including fund names, share counts, latest tracked quarter, and position changes when available.

Is URGN research on Rallies investment advice?

No. Rallies provides research, data, and educational context for URGN. It does not provide personalized investment advice.

URGN (UroGen Pharma Ltd. Ordinary Shares) Stock Analysis - Hedge Fund Holdings

UroGen Pharma Ltd. Ordinary Shares (URGN) is a publicly traded Healthcare sector company. As of May 21, 2026, URGN trades at $30.03 with a market cap of $1.39B and a P/E ratio of -10.77. URGN moved +6.99% today. Year to date, URGN is +36.56%; over the trailing twelve months it is +300.80%. Its 52-week range spans $3.42 to $32.37. Analyst consensus is strong buy with an average price target of $39.29. Rallies surfaces URGN's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

Who owns URGN stock?

Hedge funds tracked by Rallies that own URGN include Orbimed Advisors, Panagora Asset, and Farallon Capital. The latest tracked quarter is Mar 31, 2026. Rallies shows current holdings, share counts, position changes, and 13F ownership context for UroGen Pharma Ltd. Ordinary Shares.

URGN Key Metrics

Key financial metrics for URGN
Metric	Value
Price	$30.03
Market Cap	$1.39B
P/E Ratio	-10.77
EPS	$-2.74
Dividend Yield	0.00%
52-Week High	$32.37
52-Week Low	$3.42
Volume	7.34K
Avg Volume	0
Revenue (TTM)	$140.49M
Net Income	$-133.22M
Gross Margin	89.85%

Top Hedge Funds Holding URGN

Orbimed Advisors holds 875.49K shares of URGN, changed +0.00% as of Mar 31, 2026.
Panagora Asset holds 98.06K shares of URGN, changed +32.41% as of Mar 31, 2026.
Farallon Capital holds 11.00K shares of URGN, changed +0.00% as of Mar 31, 2026.

Latest URGN News

UroGen Raises Price Target to $39 After Q1 Sales Double to $29.2M — May 7, 2026
UroGen Launches LG-UTUC Luminaries, Honors Leaders in Care for 6,000-7,000 Annual Patients — Apr 8, 2026
UroGen Achieves 72.2% Two-Year Event-Free Rate with ZUSDURI — Mar 30, 2026
UroGen-Backed Survey Reveals 80% Fear Recurrence, Many Undergo 15+ Cystoscopies — Mar 13, 2026
UroGen Pharma Q4 Revenue $37.8M Beats Estimates, Narrows Loss to $0.54 — Mar 2, 2026

Recent URGN Insider Trades

Schoenberg Mark sold 10.00K (~$300.00K) on May 8, 2026.
Smith Jason Drew sold 2.65K (~$52.26K) on Feb 3, 2026.
Smith Jason Drew sold 1.61K (~$31.66K) on Feb 3, 2026.

URGN Analyst Consensus

7 analysts cover URGN: 0 strong buy, 7 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $39.29.

Common questions about URGN

Who owns URGN stock?: Hedge funds tracked by Rallies that own URGN include Orbimed Advisors, Panagora Asset, and Farallon Capital. The latest tracked quarter is Mar 31, 2026. Rallies shows current holdings, share counts, position changes, and 13F ownership context for UroGen Pharma Ltd. Ordinary Shares.
Does Rallies show 13F holders for URGN?: Yes. Rallies tracks hedge fund and 13F ownership data for URGN, including fund names, share counts, latest tracked quarter, and position changes when available.
Is URGN research on Rallies investment advice?: No. Rallies provides research, data, and educational context for URGN. It does not provide personalized investment advice.